ICCM

Key Statistics

Latest News

Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board

PR Newswire 14 hours ago

IceCure Medical completes 5-year follow up study in kidney cancer cryoablation

TipRanks 3 days ago

IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026

PR Newswire 4 days ago

IceCure Announces Thomas Hospital of Infirmary Health Installs ProSense®, Becomes First Hospital in Alabama to Offer Breast Cancer Cryoablation

PR Newswire Feb 19, 2026

IceCure Announces Shero Imaging is First to Offer Breast Cancer Cryoablation Procedures in Missouri with ProSense®

PR Newswire Feb 11, 2026

Community Sentiment

Sign in to vote

0 votes

Discussion (0)

About IceCure Medical Ltd.

IceCure Medical Ltd, a commercial stage medical device company, researches, develops, and markets cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers ProSense system, a single probe system for the treatment of malignant breast tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.